pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ZEPBOUND · news · pharmadog
← back to ZEPBOUND
News mentioning ZEPBOUND
69
stories
11h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
1d
Enveda’s exercise-simulating obesity tablet clears early clinical test
biospace
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
3d
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
7d
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
stat
9d
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
9d
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
Lilly once again beats expectations as tirzepatide accounts for 64% of revenue
endpoints
15d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
21d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
22d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
24d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
27d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
27d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
28d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
28d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
28d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
← prev
page 1 of 3
next →
